Clinical delivery of pharmacogenetic testing services: A proposed partnership between genetic counselors and pharmacists

Pharmacogenomics

Volumn 14, Issue 8, 2013, Pages 957-968

  Mills, Rachel ^a   Haga, Susanne B ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

delivery models; pharmacogenetic testing; team based care

Indexed keywords

ABACAVIR; APOLIPOPROTEIN E; CYTOCHROME P450 2C9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ALZHEIMER DISEASE; APOE GENE; CLINICAL PATHWAY; COMMUNICATION SKILL; COOPERATION; CYP2C9 GENE; DECISION MAKING; DRUG MONITORING; DRUG SAFETY; EMBOLISM; GENETIC COUNSELING; GENETIC COUNSELOR; GENETIC SCREENING; HEALTH CARE DELIVERY; HUMAN; INCIDENTAL FINDING; INFORMED CONSENT; MEDICATION THERAPY MANAGEMENT; PARAMEDICAL PERSONNEL; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACIST; PHARMACOGENETICS; REIMBURSEMENT; REVIEW; THROMBOEMBOLISM; VKORC1 GENE;

GENETIC COUNSELING; HUMANS; PATIENT CARE TEAM; PHARMACISTS; PHARMACOGENETICS; PROFESSIONAL ROLE;

EID: 84878888147     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.76     Document Type: Review

References (114)

1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
2. Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).
3. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 4(6), 354-358 (2004). (Pubitemid 39600050)
4. Lesko LJ, Zineh I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 11(4), 507-512 (2010).
5. Pulley JM, Denny JC, Peterson JF et al. Operational implementation of prospective genotyping for personalized medicine: the design of the vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92(1), 87-95 (2012).
6. Schildcrout JS, Denny JC, Bowton E et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92(2), 235-242 (2012).
7. Roederer MW. NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice. Pharmacogenomics 13(11), 1307-1313 (2012).
8. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 82(4), 388-394 (2012).
9. Payne K, Fargher EA, Roberts SA et al. Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences. Value Health 14(1), 121-134 (2011).
10. Fargher EA, Eddy C, Newman W et al. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8(11), 1511-1519 (2007). (Pubitemid 350286396)
11. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu. Rev. Genomics Hum. Genet. 12, 217-244 (2011).
12. Callard A, Newman W, Payne K. Delivering a pharmacogenetic service: is there a role for genetic counselors? J. Genet. Counsel. 21(4), 527-535 (2012).
13. Haga SB, Tindall G, O'Daniel JM. Professional perspectives about pharmacogenetic testing and managing ancillary findings. Genet. Test. Mol. Biomarkers 16(1), 21-24 (2012).
14. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158(1), 183-193 (2001). (Pubitemid 32735483)
15. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1 5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609-1616 (2009).
16. Coon KD, Myers AJ, Craig DW et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry 68(4), 613-618 (2007). (Pubitemid 46663046)
17. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123), 921-923 (1993). (Pubitemid 23275809)
18. Ellingrod VL, Moline J. Incorporating pharmacogenomics into practice. J. Pharm. Pract. 20, 277-282 (2007).
19. Haga SB, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet. Med. 10(6), 391-395 (2008).
20. O'Daniel JM. The prospect of genome-guided preventive medicine: a need and opportunity for genetic counselors. J. Genet. Counsel. 19(4), 315-327 (2010).
21. Haga S, O'Daniel J, Tindall G, Mills R, Lipkus I, Agans R. Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing. Clin. Genet. 82(2), 115-120 (2012).
22. Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 'early adopting' departments of psychiatry. J. Clin. Psychiatry 71(6), 745-753 (2010).
23. Kessler S. Psychological aspects of genetic counseling. IX. Teaching and counseling. J. Genet. Counsel. 6(3), 287-295 (1997). (Pubitemid 127716881)
24. Newman W, Murphy B, Callard A, Payne K. A role for genetic counsellors and clinical geneticists in pharmacogenetics? Clin. Genet. 82(2), 201-202 (2012).
25. Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W. Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 7(1), 49-59 (2006).
26. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. Genet. Med. 13(8), 723-728 (2011).
27. Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J. 8(2), 85-89 (2008). (Pubitemid 351411544)
28. Ashley EA, Butte AJ, Wheeler MT et al. Clinical assessment incorporating a personal genome. Lancet 375(9725), 1525-1535 (2010).
29. Ormond KE, Wheeler MT, Hudgins L et al. Challenges in the clinical application of whole-genome sequencing. Lancet 375(9727), 1749-1751 (2010).
30. Faruki H, Heine U, Brown T, Koester R, Lai-Goldman M. HLA-B 5701 clinical testing: early experience in the United States. Pharmacogenetics Genomics 17(10), 857-860 (2007). (Pubitemid 47462298)
31. Voelker R. Children's deaths linked with postsurgical codeine. JAMA 308(10), 963 (2012).
32. Kelly LE, Rieder M, van den Anker J et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 129(5), e1343-e1347 (2012).
33. Brock TP, Valgus JM, Smith SR, Summers KM. Pharmacogenomics: implications and considerations for pharmacists. Pharmacogenomics 4(3), 321-330 (2003). (Pubitemid 36546612)
34. Clemerson JP, Payne K, Bissell P, Anderson C. Pharmacogenetics, the next challenge for pharmacy? Pharm. World Sci. 28(3), 126-130 (2006). (Pubitemid 44584044)
35. Johnson JA, Bootman JL, Evans WE et al. Pharmacogenomics: a scientific revolution in pharmaceutical sciences and pharmacy practice. Report of the 2001-2002 Academic Affairs Committee. Am. J. Pharmaceut. Educ. 66(Winter Suppl.), S12-S15 (2002).
36. Corkindale D, Ward H, McKinnon R. Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. Per. Med. 4(2), 191-199 (2007). (Pubitemid 46845899)
37. Nickola TJ, Green JS, Harralson AF, O'Brien TJ. The current and future state of pharmacogenomics medical education in the USA. Pharmacogenomics 13(12), 1419-1425 (2012).
38. Kennedy MJ, Phan H, Benavides S, Potts A, Sorensen S. The role of the pediatric pharmacist in personalized medicine and clinical pharmacogenomics for children: pediatric pharmacogenomics working group. J. Pediatr. Pharmacol. Ther. 16(2), 118-122 (2011).
39. Report of the 2010 APhA House of Delegates: actions of the legislative body of the American Pharmacists Association. J. Am. Pharm. Assoc. 50(4), 471-472 (2010).
40. Simmons-Yon A, Roth MT, Vu M, Kavalieratos D, Weinberger M, Rao JK. Understanding pharmacists' experiences with advice-giving in the community pharmacy setting: a focus group study. Patient Educ. Counsel. 89(3), 476-483 (2012).
41. Albanese NP, Rouse MJ. Scope of contemporary pharmacy practice: roles, responsibilities, and functions of pharmacists and pharmacy technicians. J. Am. Pharm. Assoc. 50(2), e35-e69 (2010).
42. Smith M, Bates DW, Bodenheimer T, Cleary PD. Why pharmacists belong in the medical home. Health Aff. (Millwood). 29(5), 906-913 (2010).
43. Hammond RW, Schwartz AH, Campbell MJ et al. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy 23(9), 1210-1225 (2003). (Pubitemid 37158791)
44. Russell Teagarden J, Stanek EJ. On pharmacogenomics in pharmacy benefit management. Pharmacotherapy 32(2), 103-111 (2012).
45. McCullough KB, Formea CM, Berg KD et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharmaceut. Educ. 75(3), 51 (2011).
46. Roederer M, van Riper M, Valgus J, Knafl G, McLeod H. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Per. Med. 9(1), 19-27 (2012).
47. Brock TP, Faulkner CM, Williams DM, Smith SR. Continuing-education programs in pharmacogenomics for pharmacists. Am. J. Health Syst. Pharm. 59(8), 722-725 (2002). (Pubitemid 34407157)
48. El-Ibiary SY, Cheng C, Alldredge B. Potential roles for pharmacists in pharmacogenetics. J. Am. Pharm. Assoc. 48(2), e21-e29; quiz e30-e32 (2008).
49. Crews KR, Cross SJ, McCormick JN et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm. 68(2), 143-150 (2011).
50. O'Connor SK, Ferreri SP, Michaels NM et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 13(8), 955-962 (2012).
51. Padgett L, O'Connor S, Roederer M, McLeod H, Ferreri S. Pharmacogenomics in a community pharmacy: ACT now. J. Am. Pharm. Assoc. 51(2), 189-193 (2011).
52. Swen JJ, van der Straaten T, Wessels JA et al. Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. Eur. J. Clin. Pharmacol. 68(4), 363-370 (2012).
53. van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in the Netherlands. Drug Saf. 32(3), 255-264 (2009).
54. United States. Omnibus budget reconciliation Act of 1990 [5 November 1990. Excerpts]. Digest Public Gen. Bills 101 Pt 2(1), 213, 217-219 (1990).
55. American Pharmacists Association; National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J. Am. Pharm. Assoc. 48(3), 341-353 (2008).
56. Bluml BM. Definition of medication therapy management: development of professionwide consensus. J. Am. Pharm. Assoc. 45(5), 566-572 (2005). (Pubitemid 46037267)
57. Oladapo AO, Rascati KL. Review of survey articles regarding medication therapy management (MTM) services/programs in the United States. J. Pharm. Pract. 25(4), 457-470 (2012).
58. Cranor CW, Christensen DB. The Asheville Project: Short-term outcomes of a community pharmacy diabetes care program. J. Am. Pharm. Assoc. 52(6), 838-850 (2012).
59. Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J. Am. Pharm. Assoc. 49(3), 383-391 (2009).
60. Barnett MJ, Frank J, Wehring H et al. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J. Manag. Care Pharm. 15(1), 18-31 (2009).
61. Doucette WR, Witry MJ, Farris KB, McDonough RP. Community pharmacist-provided extended diabetes care. Ann. Pharmacother. 43(5), 882-889 (2009).
62. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J. Am. Pharm. Assoc. 49(2), 164-170 (2009).
63. Touchette DR, Masica AL, Dolor RJ et al. Safety-focused medication therapy management: a randomized controlled trial. J. Am. Pharm. Assoc. 52(5), 603-612 (2012).
64. Welch EK, Delate T, Chester EA, Stubbings T. Assessment of the impact of medication therapy management delivered to home-based Medicare beneficiaries. Ann. Pharmacother. 43(4), 603-610 (2009).
65. Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated health care system. J. Manag. Care Pharm. 16(3), 185-195 (2010).
66. Brummel AR, Soliman AM, Carlson AM, de Oliveira DR. Optimal diabetes care outcomes following face-to-face medication therapy management services. Popul. Health Manag. 16(1), 28-34 (2013).
67. Reiss SM. Integrating pharmacogenomics into pharmacy practice via medication therapy management. J. Am. Pharm. Assoc. 51(6), e64-e74 (2011).
68. Shaw L, Burckhard G. Therapeutic drug monitoring and pharmacogenetics interface considerations. In: Laboratory Medicine Practice Guidelines: Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice. Valdes R, Payne DA, Linder MW (Eds). National Academy of Clinical Biochemistry (NACB), Washington, DC, USA, 29-34 (2010).
69. Bein B. AMA delegates adopt AAFP's joint principles of patient-centered medical home. Ann. Fam. Med. 7(1), 86-87 (2009).
70. American College of Emergency Physicians. The patient-centered medical home model. Ann. Emerg. Med. 53(2), 289-291 (2009).
71. Backer LA. Building the case for the patient-centered medical home. Fam. Pract. Manag. 16(1), 14-18 (2009).
72. Berdine HJ, Skomo ML. Development and integration of pharmacist clinical services into the patient-centered medical home. J. Am. Pharm. Assoc. 52(5), 661-667 (2012).
73. Kadafour M, Haugh R, Posin M, Kayser SR, Shin J. Survey on warfarin pharmacogenetic testing among anticoagulation providers. Pharmacogenomics 10(11), 1853-1860 (2009).
74. Burton H, Shuttleworth A. Genetics education for pharmacists. Pharm. J. 270(7232), 84-85 (2003). (Pubitemid 36157290)
75. Formea CM, Nicholson WT, McCullough KB et al. Development and evaluation of a pharmacogenomics educational program for pharmacists. Am. J. Pharm. Educ. 77(1), 10 (2013).
76. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5(5), 571-579 (2004). (Pubitemid 39023073)
77. Gurwitz D, Lunshof JE, Dedoussis G et al. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J. 5(4), 221-225 (2005). (Pubitemid 41131714)
78. Anderson C, Bates I, Beck D et al. The WHO UNESCO FIP pharmacy education taskforce. Hum. Resour. Health 7, 45 (2009).
79. McKinnon R, Anderson C. Transforming pharmaceutical education to accelerate the acceptance and implementation of personalized medicine. Am. J. Pharm. Educ. 75(6), 107 (2011).
80. Cavallari LH, Overholser BR, Anderson D et al. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. Pharmacotherapy 30(6), 626 (2010).
81. Cavallari HL, Overholser BR, Anderson D et al. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. Pharmacotherapy 30(6), 228e-235e (2010).
82. Latif DA. Pharmacogenetics and pharmacogenomics instruction in schools of pharmacy in the USA: is it adequate? Pharmacogenomics 6(4), 317-319 (2005). (Pubitemid 40916356)
83. Murphy JE, Green JS, Adams LA, Squire RB, Kuo GM, McKay A. Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am. J. Pharm. Educ. 74(1), 7 (2010).
84. Netzer C, Biller-Andorno N. Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics 18(4), 344-360 (2004). (Pubitemid 38988456)
85. Robertson JA. Consent and privacy in pharmacogenetic testing. Nat. Genet. 28(3), 207-209 (2001). (Pubitemid 32626017)
86. Skirton H, Arimori N, Aoki M. A historical comparison of the development of specialist genetic nursing in the United Kingdom and Japan. Nurs. Health Sci. 8(4), 231-236 (2006). (Pubitemid 44660636)
87. Williams JK, Skirton H, Reed D, Johnson M, Maas M, Daack-Hirsch S. Genetic counseling outcomes validation by genetics nurses in the UK and US. J. Nurs. Scholarsh. 33(4), 369-374 (2001). (Pubitemid 33620502)
88. Lea DH, Williams JK, Cooksey JA, Flanagan PA, Forte G, Blitzer MG. U.S. genetics nurses in advanced practice. J. Nurs. Scholarsh. 38(3), 213-218 (2006). (Pubitemid 44252874)
89. Almarsdottir AB, Bjornsdottir I, Traulsen JM. A lay prescription for tailor-made drugs-focus group reflections on pharmacogenomics. Health Policy 71(2), 233-241 (2005). (Pubitemid 39650956)
90. Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 12(3), 197-204 (2012).
91. Haddy CA, Ward HM, Angley MT, McKinnon RA. Consumers' views of pharmacogenetics-a qualitative study. Res. Soc. Adm. Pharm. 6(3), 221-231 (2010).
92. Haga SB, Kawamoto K, Agans R, Ginsburg GS. Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results. Genet. Med. 13(10), 887-890 (2011).
93. Kaae S, Traulsen JM, Norgaard LS. Customer interest in and experience with various types of pharmacy counselling-a qualitative study. Health Expect. doi:10.1111/hex.12003 (2012) (Epub ahead of print).
94. Ikediobi ON, Shin J, Nussbaum RL et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86(1), 28-31 (2009).
95. Daly AK. Pharmacogenomics of adverse drug reactions. Genomics Med. 5(1), 5 (2013).
96. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J. Pharm. Pract. 25(4), 417-427 (2012).
97. Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br. J. Clin. Pharmacol. 74(4), 698-721 (2012).
98. Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G. APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J. 9(4), 248-257 (2009).
99. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999). (Pubitemid 29103806)
100. de Souza JA, Olopade OI. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin. Oncol. 38(2), 263-273 (2011).
101. Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 89(6), 784-785 (2011).
102. Braff JP, Chatterjee B, Hochman M et al. Patient-tailored medicine, part two: personalized medicine and the legal landscape. J. Health Life Sci. Law 2(2), 1-3, 5-43 (2009).
103. Donovan MJ. Legal issues stemming from the advancement of pharmacogenomics. UCLA J. Law Technol. 14, 35 (2010).
104. Evans BJ. Finding a liability-free space in which personalized medicine can bloom. Clin. Pharmacol. Ther. 82(4), 461-465 (2007). (Pubitemid 47414358)
105. Daly AK. Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv. Pharmacol. 63, 137-167 (2012).
106. Cordero P, Ashley EA. Whole-genome sequencing in personalized therapeutics. Clin. Pharmacol. Ther. 91(6), 1001-1009 (2012).
107. Gustafson SL, Pfeiffer G, Eng C. A large health system's approach to utilization of the genetic counselor CPT(R) 96040 code. Genet. Med. 13(12), 1011-1014 (2011).
108. Harrison TA, Doyle DL, McGowan C et al. Billing for medical genetics and genetic counseling services: a national survey. J. Genet. Counsel. 19(1), 38-43 (2010).
109. Mester JL, Trepanier AM, Harper CE, Rozek LS, Yashar BM, Uhlmann WR. Perceptions of licensure: a survey of Michigan genetic counselors. J. Genet. Counsel. 18(4), 357-365 (2009).
110. Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 50, 423-437 (2010).
111. Hresko A, Haga S. Insurance coverage policies for personalized medicine. J. Pers. Med. 2(4), 201-216 (2012).
112. Miller I, Ashton-Chess J, Spolders H et al. Market access challenges in the EU for high medical value diagnostic tests. Per. Med. 8(2), 137-148 (2011).
113. Epstein RS, Frueh FW, Geren D et al. Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics 10(1), 149-151 (2009).
114. Frueh FW. Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics 11(5), 657-660 (2010).